Provider/Grant Support
Jointly provided by P2P Syncro and Partners for Advancing Clinical Education.
This activity is supported by an independent educational grant from Kyowa Kirin.
Credits Available
- Physicians — maximum of 1 AMA PRA Category 1 Credits™
- Nurses — 1 ANCC Contact Hour
- Physician Assistants — 1 AAPA Category 1 CME Credit
- Pharmacists — 1 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of providers in primary care, pediatrics, endocrinology, rheumatology, neurology, nephrology, orthopedic surgery, emergency medicine, urgent care, geriatrics, and genetics.
Program Overview
Tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH) are two FGF23 mediated skeletal disorders. TIO occurs mostly in adults. XLH presents in early childhood. In both disorders, hypophosphatemia is a cardinal sign, and serum phosphate should be measured as the initial test. In this activity, when to raise suspicion and how to diagnose TIO and XLH will be discussed. Treatment approaches and the role of FGF23 inhibitors will be addressed.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify mechanisms and clinical features of TIO and XLH, along with the initial test to be conducted.
- Outline steps in diagnosing TIO and XLH, while recognizing common misdiagnoses and differentials.
- Develop plans to incorporate FGF23 targeted therapy into the care of patients with TIO and XLH.
Faculty
Aliya Khan, MD
Clinical Professor of Medicine
Endocrinology and Geriatrics
McMaster University, Canada
Heide Siggelkow, MD
Medical Director
Center for Endocrinology, Osteology, Rheumatology, Nuklear Medicine and Human Genetics,
University Medicine of Goettingen, Germany.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and P2P Syncro. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Education
Partners for Advancing Clinical Education designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-26-188-H01-P)
Type of Activity: Knowledge
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until June 2, 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflict of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Aliya Khan
- Consultant/Advisor/Speaker: Ascendis, Alexion, Amoylt, Amgen, Calcilytix.
Dr. Heide Siggelkow
- Consultant/Advisor/Speaker: Amgen, UCB, Kyowa Kirin, Ipsen, Ascendis, Bridge Bio, Theramex, Novo Nordisk.
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from May 31, 2026 through June 2, 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test
- Complete the activity evaluation
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. Certificates will be available for the participant to download.
For Pharmacists: Upon successfully completing the post-test with a score of 70% or better (if applicable) and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
Course Viewing Requirements
Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com